Clinical Trial Update: Combigan Ophthalmic Solution(Brimonidine 0.2% and Timolol 0.5%)With Latanoprost Compared With Latanoprost Monotherapy [Phase 4]

View source ↗

Summary

Phase 4 trial comparing Combigan ophthalmic solution (brimonidine 0.2% and timolol 0.5%) with latanoprost monotherapy for glaucoma; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glaucoma

Drugs mentioned

• Combigan Ophthalmic Solution (Brimonidine; Timolol)
• Latanoprost (Latanoprost)

Snippet

Sponsor: Genovate Biotechnology Co., Ltd., | Conditions: Glaucoma | Phase 4 | Status: UNKNOWN